Physician profile
Abdulsalam Jamous
NPI 1891778221
$19,000.97
in general payments reported to CMS, 2019-2025
44 companies · $7,420 in 2025
The $7,420 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,857 · 2020: $1,725 · 2021: $1,183 · 2022: $2,753 · 2023: $2,209 · 2024: $1,854 · 2025: $7,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,598 · Food and Beverage: $4,397 · Travel and Lodging: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,598.34 |
| Food and Beverage | $4,397.39 |
| Travel and Lodging | $1,487.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,987.28 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,168.58 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,530.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,258.61 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Veran Medical Technologies, INC. | $736.88 | 2019-2020 | |
| Genzyme Corporation | $697.57 | 2019-2025 | |
| Insmed, INC. | $630.70 | 2019-2025 | Arikayce |
| Ethicon INC. | $579.24 | 2022 | |
| Olympus Corporation of The Americas | $540.19 | 2022 | |
| Electromed, INC. | $411.80 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $393.07 | 2020-2024 | Xywav |
| Regeneron Healthcare Solutions, INC. | $341.36 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $181.86 | 2020-2024 | Glassia |
| Resmed Corp | $180.08 | 2019-2024 | |
| Genentech USA, INC. | $179.85 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $175.22 | 2019 | |
| Merck Sharp & Dohme LLC | $173.18 | 2019-2024 | Zerbaxa, Recarbrio |
| Grifols USA, LLC | $172.75 | 2019-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $171.56 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $156.12 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $111.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $107.93 | 2019-2022 | |
| Axsome Therapeutics, INC. | $98.52 | 2023-2024 | Sunosi |
| Philips North America LLC | $98.29 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $90.66 | 2020-2021 | |
| Harmony Biosciences LLC | $90.01 | 2021-2023 | Wakix |
| Mallinckrodt Hospital Products INC. | $81.71 | 2021-2022 | |
| Pfizer INC. | $77.58 | 2019-2024 | |
| Shionogi INC | $67.67 | 2024-2025 | Fetroja |
| Baxter Healthcare | $65.57 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $61.16 | 2025 | Ohtuvayre |
| Circassia INC. | $58.86 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $53.72 | 2019-2023 | Opsumit |
| United Therapeutics Corporation | $47.47 | 2022-2024 | Tyvaso |
| Advanced Respiratory, INC | $34.72 | 2019 | |
| Eisai INC. | $31.94 | 2020-2021 | |
| Pinnacle Biologics, INC | $25.03 | 2024 | Photofrin |
| Paratek Pharmaceuticals, INC. | $22.63 | 2022 | |
| Monaghan Medical Corporation | $21.16 | 2024 | Aerochamber |
| Optinose US, INC. | $20.69 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.34 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $16.66 | 2025 | Lumryz |
| Pulmonx Corporation | $16.10 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Fisher & Paykel Healthcare INC | $15.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdulsalam Jamous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.